Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Table 2

Outcomes of uni- and multivariate analysis.

Factor	OS			PFS
	Univariate; value	Multivariate; value	HR	Univariate; value	Multivariate; value	HR
Age group (<70 vs. ≥70 y)	0.74	—	—	0.69	—	—
Gender (female vs. male)	0.78	—	—	0.83	—	—
ECOG (0 vs. 1)	0.89	—	—	0.76	—	—
Tumor location (H vs. B/T)	0.76	—	—	0.84	—	—
N-stage (0 vs. 1)	0.006	0.011	2.49	0.012	0.018	2.66
CA 19-9 (< vs. ≥ 90 U/m/L)	0.014	0.019	1.53	0.008	0.015	2.10
SIRI (< vs. ≥1.6)	<0.001	<0.001	2.97	<0.001	<0.001	3.31

Abbreviations: OS: overall survival; PFS: progression-free survival; HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; H: head; B/H: body/tail; N-stage: nodal stage; CA 19-9: cancer antigen 19-9; SIRI: systemic inflammation response index.